• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Smith+Nephew announces positive data in Regeneten bioinductive implant study

Smith+Nephew announces positive data in Regeneten bioinductive implant study

September 14, 2022 By Sean Whooley

marketing image of Smith+Nephew Regeneten Bioinductive Implant
The Regeneten bioinductive implant [Image from Smith+Nephew]
Smith+Nephew (NYSE:SNN) announced today that data supports the use of its Regeneten bioinductive implant in rotator cuff repair.

London-based Smith+Nephew designed Regeneten to provide a patient-centric treatment supporting the body’s natural healing process. The aim is for the implant to change the course of tear progression, aid return to normal activity and reduce re-tears compared to conventional surgery.

Interim analysis from a randomized controlled trial showed a significant reduction in the re-tear rate of full-thickness rotator cuff repairs when using Regeneten, according to a news release. Re-tear rates of patients with medium to large full-thickness tears were measured following either an arthroscopic supraspinatus transosseous equivalent (TOE) repair alone, or the same TOE repair with the addition of a Regeneten implant.

Dr. Miguel Angel Ruiz-Ibán of Hospital Universitario Ramon Y Cajal, Madrid, Spain, presented results at the 2022 SECEC-ESSE Congress in Dublin, Ireland.

“Traditional rotator cuff procedures and the resulting re-tear rates present a challenge and a concern for both surgeons and patients alike,” said Dr. Ruiz-Ibán. “The interim results from this RCT are encouraging and indicate that the Smith+Nephew Regeneten bioinductive implant may significantly improve re-tear rates. I look forward to the completion of this investigation in 2023 and further use of the implant.”

Smith+Nephew reports positive re-tear rate results

At 12-month follow-up, patients who received a Regeneten implant had a re-tear rate of 3.5%. Patients who received a TOE repair alone had a re-tear rate of 25%. That rate is in line with published rates on similar tear types, Smith+Nephew said. The study observed no differences in postoperative complications between groups.

“New RCT evidence supporting the use of our Regeneten bioinductive implant for improved patient outcomes continues to grow,” said Christie Van Geffen, VP sports medicine joint repair at Smith+Nephew. “No other bioinductive treatment has the amount of science behind it supporting the clinical value for thousands of patients with rotator cuff tears.”

Filed Under: Clinical Trials, Featured, Implants, News Well, Orthopedics Tagged With: Smith+Nephew

More recent news

  • Cognixion, Blackrock Neurotech ink distro deal for BCI tech
  • AdvaMed calls for medtech tariff exemptions at Senate hearing
  • GE HealthCare, Raydiant Oximetry partner on fetal oxygen saturation tech
  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy